REFERENCES
1. Hui DS, E IA, Madani TA, Ntoumi F, Kock R, Dar O, et al. The
continuing 2019-nCoV epidemic threat of novel coronaviruses to global
health - The latest 2019 novel coronavirus outbreak in Wuhan, China. Int
J Infect Dis. 2020;91:264-6.
2. Organization WH. WHO Director-General’s remarks at the media briefing
on 2019-nCoV on 11 February 2020. Internet] World Health Organization.
2020.
3. COVID-19 Dashboard by the Center for Systems Science and Engineering
(CSSE) at Johns Hopkins University (JHU) [Available from:
https://coronavirus.jhu.edu/map.html.
4. Yu N, Li W, Kang Q, Xiong Z, Wang S, Lin X, et al. Clinical features
and obstetric and neonatal outcomes of pregnant patients with COVID-19
in Wuhan, China: a retrospective, single-centre, descriptive study.
Lancet Infect Dis. 2020;20(5):559-64.
5. Qi H, Luo X, Zheng Y, Zhang H, Li J, Zou L, et al. Safe delivery for
pregnancies affected by COVID-19. Bjog. 2020.
6. Ministry TRH. Current Situation in Turkey 2020 [updated June 2,
2020. Available from: https://covid19.saglik.gov.tr.
7. Prevention CCfDCa. How to Protect Yourself & Others [Available
from:
https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/prevention.html.
8. Panahi L, Amiri M, Pouy S. Risks of Novel Coronavirus Disease
(COVID-19) in Pregnancy; a Narrative Review. Arch Acad Emerg Med.
2020;8(1):e34.
9. Wong SF, Chow KM, Leung TN, Ng WF, Ng TK, Shek CC, et al. Pregnancy
and perinatal outcomes of women with severe acute respiratory syndrome.
American journal of obstetrics and gynecology. 2004;191(1):292-7.
10. Schwartz DA. An Analysis of 38 Pregnant Women with COVID-19, Their
Newborn Infants, and Maternal-Fetal Transmission of SARS-CoV-2: Maternal
Coronavirus Infections and Pregnancy Outcomes. Arch Pathol Lab Med.
2020.
11. Thornton JG. COVID-19 in pregnancy. Bjog. 2020.
12. Zaigham M, Andersson O. Maternal and perinatal outcomes with
COVID-19: A systematic review of 108 pregnancies. Acta Obstet Gynecol
Scand. 2020.
13. Mullins E, Evans D, Viner RM, O’Brien P, Morris E. Coronavirus in
pregnancy and delivery: rapid review. Ultrasound Obstet Gynecol.
2020;55(5):586-92.
14. Di Mascio D, Khalil A, Saccone G, Rizzo G, Buca D, Liberati M, et
al. Outcome of Coronavirus spectrum infections (SARS, MERS, COVID 1 -19)
during pregnancy: a systematic review and meta-analysis. Am J Obstet
Gynecol MFM. 2020;2(2):100107.
15. Rasmussen SA, Smulian JC, Lednicky JA, Wen TS, Jamieson DJ.
Coronavirus Disease 2019 (COVID-19) and pregnancy: what obstetricians
need to know. Am J Obstet Gynecol. 2020;222(5):415-26.
16. Ferrazzi E, Frigerio L, Savasi V, Vergani P, Prefumo F, Barresi S,
et al. Vaginal delivery in SARS-CoV-2-infected pregnant women in
Northern Italy: a retrospective analysis. Bjog. 2020.
17. Della Gatta AN, Rizzo R, Pilu G, Simonazzi G. Coronavirus disease
2019 during pregnancy: a systematic review of reported cases. Am J
Obstet Gynecol. 2020.
18. Li M, Lei P, Zeng B, Li Z, Yu P, Fan B, et al. Coronavirus Disease
(COVID-19): Spectrum of CT Findings and Temporal Progression of the
Disease. Acad Radiol. 2020;27(5):603-8.
19. Barlow A, Landolf KM, Barlow B, Yeung SYA, Heavner JJ, Claassen CW,
et al. Review of Emerging Pharmacotherapy for the Treatment of
Coronavirus Disease 2019. Pharmacotherapy. 2020;40(5):416-37.
20. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment
is associated with decreased mortality in severe coronavirus disease
2019 patients with coagulopathy. Journal of Thrombosis and Haemostasis.
2020;18(5):1094-9.
21. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A trial of
lopinavir–ritonavir in adults hospitalized with severe Covid-19. New
England Journal of Medicine. 2020.
22. Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic
Treatments for Coronavirus Disease 2019 (COVID-19): A Review. Jama.
2020.
23. Ministry TRH. COVID-19 (SARS-CoV-2 INFECTION) (Scientific Board
Study)
ANTICYTOCIN-ANTI-INFLAMMATORY TREATMENTS, COAGULOPATHY MANAGEMENT
Ankara2020 [updated June 1,2020. Available from:
https://covid19bilgi.saglik.gov.tr/depo/rehberler/covid-19-rehberi/COVID-19_REHBERI_ANTISITOKIN-ANTI_INFLAMATUAR_TEDAVILER_KOAGULOPATI_YONETIMI.pdf.
Table 1 Demographic characteristics